Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Common Equity (2020 - 2025)

Mirum Pharmaceuticals (MIRM) has 6 years of Common Equity data on record, last reported at $314.7 million in Q4 2025.

  • For Q4 2025, Common Equity rose 39.47% year-over-year to $314.7 million; the TTM value through Dec 2025 reached $314.7 million, up 39.47%, while the annual FY2025 figure was $314.7 million, 39.47% up from the prior year.
  • Common Equity reached $314.7 million in Q4 2025 per MIRM's latest filing, up from $292.0 million in the prior quarter.
  • Across five years, Common Equity topped out at $314.7 million in Q4 2025 and bottomed at $56.4 million in Q3 2021.
  • Average Common Equity over 5 years is $184.6 million, with a median of $197.5 million recorded in 2022.
  • Peak YoY movement for Common Equity: plummeted 53.1% in 2021, then surged 200.19% in 2022.
  • A 5-year view of Common Equity shows it stood at $120.2 million in 2021, then rose by 18.16% to $142.0 million in 2022, then skyrocketed by 75.07% to $248.7 million in 2023, then fell by 9.26% to $225.6 million in 2024, then skyrocketed by 39.47% to $314.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $314.7 million in Q4 2025, $292.0 million in Q3 2025, and $255.2 million in Q2 2025.